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Cutaneous Manifestations οf 
Inflammatory Bowel Disease
Sophia Georgiou, Efi Pasmatzi, Alexandra Monastirli, Dionysios Tsambaos
A B S T R AC T
Cutaneous lesions are among the most frequent extraintestinal manifestations of IBD. 
They may precede, occur with or postdate the onset of the intestinal disease and can 
significantly contribute to the morbidity and impairment of the overall quality of life 
of the affected patients. In this article, the cutaneous manifestations of IBD are re-
viewed with particular emphasis on their clinicopathological and therapeutic aspects.
I N T RODUC T I ON
Cutaneous lesions are among the most frequent extraintestinal manifestations 
of IBD, may in some cases precede the intestinal ones [1,2] and occur in 2%-34% of 
patients with IBD[3,4], in 5%-44% of patientswith CD [5,6] and in 9%-19% of patients 
with UC [7]. It is the purpose of the present paper to review the most important and 
common cutaneous manifestations of IBD, with particular emphasis on their clinico-
pathological and therapeutic aspects. 
According to their pathogenetic mechanisms, the cutaneous manifestations of 
IBD can be classified into the following four categories [7]:
1.	 Specific	cutaneous	manifestations, whose pathogenesis is identical to that of the 
intestinal disease.
2.	 Reactive	cutaneous	manifestations, which are caused by immunological mecha-
nisms triggered by antigens shared by the gut and the skin.
3.	 Cutaneous	disorders	commonly	associated	with	IBD and
4.	 Secondary	cutaneous	manifestations, which are due either to complications of 
IBD or to adverse reactions of the treatment.
S P E C I F I C 	 C U T A N E OU S 	M A N I F E S T A T I ON S 	 O F 	 I B D
a.	 Perianal	fissures	and	fistulae: These are usually multiple, represent the most 
common skin lesions of IBD, occur mainly in CD (20%-60%) and are relatively 
rarely found in patients with UC [8,9]. They are due to direct involvement of skin 
and mucosae by the process causing the intestinal disease [10] and may precede 
the symptoms and signs of the latter by several years [9]. More commonly they af-
fect the perineum, the perianal region, the peristomal and the abdominal wall and 
often lead to the formation of abscesses, draining sinus tracts, undermined ulcers 
(that may destroy the anal sphincter) and edematous skin tags due to inflammation 
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of anal Morgagni’s crypts [7,9]. Fissures are commonly 
painless and posteriorly located, whereas fistulae arise 
either subsequent to a cryptoglandular infection or as a 
secondary complication of anal fissures.
b.	 Orofacial	CD: It occurs in 5%-20% of patients and may 
precede the typical gastrointestinal symptoms by several 
months or even years. Its manifestation and severity do 
not always correlate with either the activity of the under-
lying intestinal disease or its response to treatment [11]. 
The clinical spectrum of orofacial CD manifestations 
includes nodules of the gingiva and alveolar mucosa, 
multiple aphthae-like lesions and, occasionally, linear 
ulcers, cobblestone appearance of the buccal mucosa, 
angular cheilitis and ulceration, pyostomatitis vegetans, 
granulomatous cheilitis, indurated fissuring of the lower 
lip, gingival hyperplasia and bleeding and diffuse oral 
swelling [10]. The differential diagnosis of orofacial CD 
includes sarcoidosis, angioedema, Miescher’s cheilitis, 
cheilitis glandularis and tuberculosis [12].
c.	 Cutaneous	(metastatic)	CD: It is a rare and difficult to 
diagnose disorder most commonly affecting adult fe-
males with established intestinal CD. Its symptoms and 
signs can precede those of the latter by several months or 
years [10]. It is usually located on the extremities and the 
intertriginous areas but can occur anywhere on the body. 
There is no consistent correlation between the occurrence 
of the cutaneous lesions and the activity of the intestinal 
disorder [13] or its response to the treatment [14]. Cutane-
ous CD can be divided into two main clinical forms, the 
genital (56%) and the nongenital form (44%). The former 
more commonly occurs in children and is characterized 
by erythema, edema and fissures or ulcers of the labiae, 
scrotum or the penis [1,10,15-17]. The nongenital form 
reveals a polymorphous clinical picture consisting of 
papules or nodules, plaques with or without ulceration 
(Fig. 1), abscesses, draining sinuses, hidradenitis sup-
purativa, lobular panniculitis and scars [15,18-20]. The 
most commonly affected sites are lower extremities and 
soles (38%), trunk and abdomen (24%), upper extremities 
and palms (15%), face and lips (11%) and intertriginous 
areas (8%) [10]. Although the manifestations of cutaneous 
CD are mostly characterized by chronic course, in some 
cases they subside either spontaneously or subsequent to 
treatment [10,21]. In their clinical differential diagnosis 
a wide spectrum of diverse disorders (Table 1) should be 
considered. The confirmation of the clinical diagnosis is 
based on the histological features, which are identical to 
those of CD [22].
H ISTOPATHOlOgY
The histological features of the specific cutaneous manifes-
tation of IBD are characterized by non-caseating granulomas 
with multinucleated giant cells mostly occurring in the dermis 
and only rarely in the subcutaneous tissue, which are surrounded 
by lymphocytes, plasma cells and some eosinophils. The 
presence of the latter is characteristic for the granulomatous 
inflammation in CD, which in some instances is accompanied 
by small necrotic foci and extensive necrobiotic areas at the 
central and the peripheral parts of granulomas, respectively 
[10,20]. Histologically, the specific cutaneous manifestations 
of IBD have to be differentiated from the disorders included 
in Table 1.
PATHOgENES I S
The exact pathogenetic mechanisms of the specific cuta-
neous manifestations of IBD at the molecular level remain 
presently unknown; however, it seems likely that vasculitis 
caused by the activation of an excessive immunological response 
TABlE	1.	Clinical and histological differential diagnosis of 
cutaneous Crohn’s disease (CD)
Infections
 Mycobacterial infections
 Tuberculoid leprosy
 Cutaneous mycoses
 Lymphogranuloma venereum
 Granuloma inguinale
 Schistosomiasis
 Erysipelas
granulomatous	disorders
 Cutaneous sarcoidosis
 Cheilitis granulomatosa
 Necrobiotic granuloma annulare
 Zirconium granuloma
 Foreign body reactions
 Berylliosis
Miscellaneous
 Hidradenitis suppurativa (acne inversa)
 Obstruction-induced chronic lymphedema
FIgURE	1. Clinical features of cutaneous (metastatic) Crohn’s 
disease.
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to antigens released subsequent to damage of the intestinal 
mucosal barrier in genetically predisposed patients may be 
responsible for the occurrence of the cutaneous and the other 
extraintestinal manifestations of IBD [20,23].
TR EATMENT
Apart from the management of the underlying intestinal 
disease, the treatment of the specific cutaneous manifestations 
of IBD includes the following modalities:
I. Perianal fissures
In our Department, the mainstay of the treatment of peri-
anal fissures is the topical application of glycerine trinitrate 
0.2% ointment [24] followed in several cases by symptomatic 
lesions by botulinum injections into the anal sphincter. In rare 
cases, showing only limited response to these compounds, 
calcium channel antagonists (diltiazem) or lateral internal 
sphincterotomy [25,26] should be considered.
II. Perianal fistulae
Surgical treatment is indicated for type I fistulae, which 
occur in intestinal areas affected by active CD and includes 
fistulotomy (particularly for low fistulae), use of flaps and 
interposition grafts, resection of proximal intestinal disease. 
Proctectomy and proctocolectomy should be performed in 
cases with severe perianal disease and rectal involvement 
[25,27,28].
Conservative pharmacologic treatment is indicated in cases 
with type II fistulae, which occur in patients with an appar-
ently normal intestinal tract [27] or in those with anastomosis, 
and mainly consists of systemic antibiotics (metronidazole, 
ciprofloxacin). In patients unresponsive to the antibiotic 
therapy, administration of immunomodulators (cyclosporine, 
mercaptopurine, azathioprine, methotrexate, infliximab) and 
oral thalidomide should be carefully considered. Only in very 
rare cases may perianal fistulae favourably respond to systemic 
steroids, aminosalicylates or mycophenolate mofetil [25].
III. Orofacial CD
Particularly in children, infliximab infusions are the 
mainstay of the treatment and lead to rapid remission [11]. 
Alternatively, clofazimine, steroids, immunosuppressants or 
thalidomide could be used [29,30].
IV. Cutaneous (metastatic) CD
According to our experience, oral metronidazole, and 
intralesional or systemic steroids are the most beneficial drugs 
for the conservative treatment of this disorder. In recalcitrant 
cases, administration of oral sulphasalazine, oral azathioprine 
(as monotherapy or in combination with 6-mercaptopurine), 
intravenous infliximab, oral zinc sulfate and hyperbaric oxy-
gen should be considered [1,10,15,30-32]. In cases with severe 
cutaneous ulcers, surgical resection under oral administration 
of zinc sulfate is indicated [10].
R E AC T I v E 	 C U T A N E OU S	
M A N I F E S T A T I ON S 	 O F 	 I B D
The reactive cutaneous manifestations of IBD include 
erythema nodosum, pyoderma gangrenosum, vesiculopustular 
eruption, pyoderma vegetans, necrotic leukocytoclastic vascu-
litis, cutaneous nodular polyarteriitis and other neutrophilic 
dermatoses.
I.	Erythema	nodosum: It is the most common cutaneous 
manifestation of IBD occurring in 3%-10% of patients with 
UC and in 4%-15% of those with CD [2,4,9,15,33], whereas 
in children it represents the most common extraintestinal 
manifestation of the disease; most affected patients are women 
aged 25-40 years [7,9,34]. Erythema nodosum may in some 
rare cases precede the manifestations of the intestinal disease 
by several years and can appear in all clinical phases of IBD; 
however, in about 20% of the patients it occurs during the 
acute phase [4,35]. In patients with CD, erythema nodosum, 
is mostly associated with colon involvement. Nevertheless, its 
occurrence in IBD correlates well with the activity but not with 
the severity or the extent of the intestinal disease [2,7,15,36].
The clinical picture of erythema nodosum is characterized 
by multiple, red or violaceous, deep-seated, non-ulcerating and 
painful subcutaneous nodules (1-3 cm in diameter), which are 
usually located on the extensor surface of the lower extremi-
ties, particularly on that of the tibiae and rarely on the trunk 
or the upper extremities, reveal a symmetrical distribution 
and in most cases show a spontaneous remission without scar 
formation. Erythema nodosum is often accompanied by fever, 
chills and arthralgia or arthritis. The latter is rarely seen in 
children, but in adults it may precede the occurrence of the 
cutaneous lesions by weeks or months [4,9].
Histologically, erythema nodosum is a diaphragmatic pan-
niculitis, which is characterized by inflammatory infiltration 
of the fibrous diaphragms of the subcutaneous tissue mainly 
consisting of neutrophils (in the early phase) and of lymphocytes 
and histiocytes (in the late phase), by acute necrotic vasculitis 
of the small venules of the diaphragms with thrombosis and 
extravasation of the erythrocytes or chronic inflammation with 
edema of the endothelial cells. In some cases, the lobules may 
be partially or totally affected by fat necrosis and neutrophilic 
infiltration [9]. Direct immunofluorescence reveals perivascular 
deposition of immunoglobulins and complement [37].
Although the underlying pathogenetic mechanisms of 
erythema nodosum remain presently unknown, it is gener-
ally thought that the characteristic cutaneous lesions of this 
disorder are due to an abnormal immunological response 
activated by the same bacterial antigens which are responsible 
for the intestinal disease [4,38]. A significant correlation of 
erythema nodosum and tumor necrosis factor (TNF) gene 
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polymorphism has been reported [39]. This gene is located 
in the region of HLA antigens class II (on the short arm of 
chromosome 6) where genes associated with the occurrence of 
arthritis, erythema nodosum and iridocyclitis are also located. 
Thus, it is possible that the genetic transmission of all these 
genes leads to the manifestation of the overlapping syndrome, 
which includes arthritis, erythema nodosum and iridocyclitis 
in patients with IBD [39-41].
The treatment of erythema nodosum mainly targets the 
underlying flare up of IBD and almost always leads to the 
remission of the cutaneous lesions [41]. According to our ex-
perience, a rapid resolution of the lesions can be achieved in 
most patients after oral administration of low doses of steroids. 
Alternatively, non-steroidal anti-inflammatory drugs, potassium 
iodide, colchicine, cyclosporine, thalidomide or dapsone can 
be used. In recalcitrant cases, intravenous administration of 
infliximab and extracorporal monocyte-granulocyte apheresis 
combined with oral 5-aminosalicylic acid may be considered 
[4,41,42].
II.	PYg represents the most severe cutaneous manifesta-
tion of IBD (2%-3%) which occurs in 5%-12% of patients with 
UC and only in 1%-2% of patients with CD, whereas about 
50% of patients with PYG also suffer from UC [2,4,15,43]. 
The correlation of PYG with the activity of the underlying 
intestinal disease is controversial. In about 75% of patients 
with CD, PYG occurs during the acute phase of the disease 
[2] whereas in some rare cases it may precede the onset of the 
intestinal symptoms by years [7,35]. The clinical picture of PYG 
is usually characterized by the spontaneous or metatraumatic 
occurrence of erythematous papulopustular lesions (Fig. 2) 
that are rapidly transformed into painful necrotic ulcers with 
edematous, violaceous, sharply circumscribed raised borders 
(Fig. 3), in which necrotic pustules may occur. The lesions are 
devoid of any bacteria, expand rapidly and heal with scar forma-
tion [4,44,45]. The ulcers are single or multiple, unilateral or 
bilateral and, in some cases, they may cover the total surface 
of an extremity. They are located on the lower extremities, the 
trunk, the face, the neck, around abdominal stomata (peris-
tomal PYG) or in surgical incision or trauma sites (pathergy). 
Apart from its classic ulcerative form, PYG may also occur in 
one of the following three clinical forms:
a.	 Pustular, characterized by multiple painful pustules with 
halo, which are not transformed into ulcers and persist 
over a period of months.
b.	 Bullous, characterized by the occurrence of bullae which 
are rapidly transformed into painful erosions and necrotic 
ulcers.
c.	 vegetans, characterized by a well demarcated superficial 
ulcer, which is gradually transformed into an exophytic 
lesion.
The clinical differential diagnosis of PYG includes a wide 
spectrum of dermatoses the most important of which are 
summarized in Table 2.
FIgURE	2. Pyoderma gangrenosum (early phase) in a patient 
with ulcerative colitis.
FIgURE	 3. Pyoderma gangrenosum (late phase) in a patient 
with ulcerative colitis.
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The histological picture of PYG is unspecific and depends 
on the clinical form, the stage of the lesions and the region of 
the ulcer the biopsy is obtained from. The most characteristic 
histological feature is a massive inflammatory infiltration in 
the dermis, which is composed by neutrophils and leads to the 
formation of abscess, colliquefaction and necrosis with second-
ary thrombosis of the middle and small vessels and extrava-
sation of erythrocytes. The occurrence of necrotic vasculitis 
(with fibrinoid, necrosis and leucocytoclastic or lymphocytic 
vasculitis) is not a constant histological feature [43,46].
An excessive immunological response to bacterial anti-
gens absorbed from the gut, due to damage of the intestinal 
mucosal barrier in genetically predisposed subjects, may be 
of essential importance for the pathogenetic mechanisms of 
erythema nodosum. Autoantibodies are thought to be formed 
against antigens shared by the gut and the hair follicles fol-
lowed by deposition of immune complexes and complement 
on the endothelial wall of dermal vessels, bacteremia, abscess 
formation and hypersensitivity vasculitis [2,43,47]. The marked 
accumulation of neutrophils seen in the lesions of PYG is 
the result of a multistage process characterized by a marked 
increase in the expression and/or release of proinflamma-
tory mediators, chemotactic or inflammatory cytokines and 
adhesion molecules. The selective occurrence of cutaneous 
lesions of PYG on the lower extremities is associated with the 
dinstinctiveness of local vascularization and the microcircula-
tion pattern which favors the excessive migration of neutrophils 
to these areas [45,48].
The mode of treatment for PYG depends on the severity 
of the disease and includes the management of the underlying 
IBD [4]. In our Department, the mainstay of treatment of the 
localized form of the disease is the intralesional and/or systemic 
steroid administration [44], whereas other groups topically 
apply either tacrolimus 0.3% or nicotine 0.5% [43,49-51] with 
varying success. In our experience, systemic steroids represent 
the treatment of choice for multiple lesions or the generalized 
form of PYG and can lead to a 50% reduction in the size of 
ulcers within one month and to a complete resolution within 
3-4 months [9,41,45]. Alternatively, the following compounds 
can be used:
Cyclosporin [4,9], sulfasalazine and dapsone, which are 
efficacious in the management of both IBD and PYG [44], 
azathioprine and 6-mercaptopurine [43], tacrolimus [43,49,52], 
mycophenolate mofetil [53,54] and infliximab [41,55,56]. 
Potassium iodate, minocycline, chlorambucil, cyclophospha-
mide, methotrexate and thalidomide have also been used in 
the management of PYG with varying success [9,11,57,58]. 
Recently, leukocytapheresis was reported to lead to a rapid 
improvement of PYG and the underlying intestinal disorder 
[59]. Due to pathergy, surgical excision of the skin lesions 
should be avoided [41].
III.	The	vesiculopustular	eruption is presently regarded as 
an abortive form of PYG that occurs not only in patients with 
UC (5%) but also in those with CD (2%) [7,60]. The eruption is 
localized or generalized, occurs during the exacerbations of the 
underlying disease and its resolution follows or coincides with 
the remission of the latter. The clinical picture is characterized 
by groups of erythematous vesiculopustular lesions (3-5 mm) 
localized on the trunk, the genogenital region (Fig. 4) and 
the extremities (without affecting palms and soles), gradually 
resolving with a post-inflammatory pigmentation. The lesions 
do not progress into the typical features of PYG possibly due 
to an impairment of inflammatory response [9].
The histological picture is characterized by interfollicular, 
subcorneal and intraepidermal neutrophilic abscesses, whereas 
in the dermis a perivascular infiltrate consisting of eosinophils, 
lymphocytes and histiocytes can be seen [61]. Treatment of 
the intestinal disease usually results in the remission of the 
vesiculopustular eruption; if this is not the case, the latter 
should be treated with the therapeutic regimens used in the 
management of PYG [9,60].
Iv.	Pyodermatitis	vegetans (regarded as a clinical form 
of PYG) and pyostomatitis	vegetans represent rare cutane-
ous manifestations of IBD, which primarily occur in patients 
with UC. Clinically, pyodermatitis vegetans is characterized 
by pustules whose rapid rupture results in the development 
of erosions with hemorrhagic and malodorous ground and 
vegetating exophytic erythematous plaques surrounded by 
pustules. These lesions are predominantly located in the 
folds and, in some cases, on the trunk and the extremities and 
gradually resolve leaving pigmented scars. Recurrences are 
not uncommon [9]. Pyostomatitis vegetans, which can precede 
TABlE	 2. Clinical differential diagnosis of pyoderma 
gangrenosum (PYG)
Infections
 Bacterial pyoderma
 Gummatous syphilis
 Deep fungal infections
 Mycobacterial infections
 Amebiasis
 Viral infections
Drug-related
 Halogenoderma
 Drug reactions
vasculopathies
 Antiphospholipid syndrome
 Systemic (or necrotizing) vasculitis
 Synergistic gangrene
Neoplasms
 Epithelial neoplasms
 Lymphomas
Miscellaneous
 Factitial ulcer
 Insect bite
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IBD by months or years, is characterized by erythema and 
thickening of the buccal mucosa with multiple pustules and 
erosions and in some cases by eosinophilia in the peripheral 
blood. The clinical differential diagnosis of both disorders 
includes pemphigus vulgaris or vegetans, bullous pemphigoid, 
epidermolysis bullosa acquisita, bullous drug eruptions, viral 
infections, erythema multiforme, Behηet’s disease and Sweet’s 
syndrome [62].
Histologically, pyodermatitis and pyostomatitis vegetans 
are characterized by a pseudoepitheliomatous hyperplasia 
with intra- or hypoepithelial abscesses containing neutrophils 
and eosinophils. The treatment of pyodermatitis vegetans is 
similar to that of PYG, whereas that of pyostomatitis vegetans 
consists of topical and systemic steroids and management of 
the underlying intestinal disease [7,63].
v.	Nlv	and	CNR represent rare cutaneous manifesta-
tions of IBD. NLV more commonly occurs in patients with 
UC, whereas CNR is exclusively seen in patients with CD 
[7]. Both disorders usually occur after the manifestation of 
the intestinal disease, but in rare cases they may precede the 
latter by months or years. The clinical course of NLV and 
CNR usually reveals no correlation with the activity of IBD 
[7,64]. The clinical features of NLV include palpable purpura, 
urticarial plaques, nodules, hemorrhagic bullae, necrotic 
ulcers and rarely gangrene. These lesions are usually located 
on the lower extremities. In some cases, cryoglobulinemia 
and systemic signs and symptoms (fever, malaise, myalgia and 
malleolar edema) may also occur.
Histology reveals a typical leucocytoclastic vasculitis of 
the post-capillary venules with infiltration by neutrophils, 
hemorrhage, necrosis of the vascular wall and fibrin deposi-
tion [64]. On immunofluorescence, deposition of IgG, IgM 
and C3 is seen in the walls of the vessels in the upper dermis 
of early lesions.
The clinical picture of CNR is characterized by painful 
erythematous nodules, ulcers and livedo reticularis most com-
monly located on the lower extremities. Peripheral neuropathy, 
arthralgia and myalgia may also be seen. On light microscopy, 
there is a necrotic leukocytoclastic vasculitis of small and 
middle diameter arteries at the lower dermis and the subcu-
tis with granulomatous inflammation (in patients with CD) 
[7,64]. Deposition of immune complexes on the arterial walls 
is most probably involved in the pathogenetic mechanisms of 
vasculitis. These immune complexes are formed upon direct 
exposure of immunocompetent cells of the affected mucosa 
of colon to focal antigens [64]. The treatment of vasculitis 
mainly includes systemic or oral steroids and management of 
the underlying intestinal disease.
VI. The most important neutrophilic dermatoses that occur 
in patients with IBD are Sweet’s	syndrome	and	the	bowel-as-
sociated	dermatosis-arthritis	syndrome [48]. Common feature 
of these disorders is the occurrence of an aseptic neutrophilic 
infiltration in the dermis and/or epidermis, the location and 
severity of which correlate well with the corresponding clini-
cal features [48].
The classical form of Sweet’s syndrome primarily occurs 
in IBD or may appear subsequent to colectomy, most com-
monly affects women [65] and is characterized by acute febrile 
onset with painful, edematous and erythematous nodules and 
plaques on the surface of which vesicles, bullae or pustules 
may be present (Fig. 5). In most cases, Sweet’s syndrome 
affects patients with respiratory or digestive infection and 
may be associated with vaccination, inflammatory disorders, 
myelohyperplastic diseases, neoplasia or pregnancy. In the 
acute phase, there is a peripheral leukocytosis with > 70% 
neutrophils, whereas a dense neutrophilic infiltration in the 
dermis is the cardinal histological feature of the cutaneous 
lesions. Systemic administration of steroids represents the 
treatment of choice. Alternatively, sulphone, colchicine and 
FIgURE	4. widespread vesiculopustular eruption in a patient 
with ulcerative colitis.
FIgURE	5. Severe form of Sweet’s syndrome in a patient with 
Crohn’s disease.
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potassium iodate [65] may be considered.
The bowel-associated dermatosis-arthritis syndrome, 
originally described as a complication of surgical jejunoileal-
bypass for morbid obesity, is known to occur in a milder 
clinical form also in patients with IBD without intestinal 
bypass [44,48,66,67]. The clinical picture of this syndrome is 
characterized by recurrent episodes of fever, rigor, malaise, 
arthritis and polyarthralgias of the upper extremities and by 
the occurrence of cutaneous lesions. The latter consist of 
erythematous, edematous and painful papules and of aseptic 
vesicles and pustules (2-4 mm in diameter), which are located 
on the upper half of the trunk and the upper extremities 
(usually on the deltoid muscle region). These lesions occur in 
crops, resolve within 1-2 weeks and relapse after 4-6 weeks 
[7,44]. The clinical differential diagnosis includes Behηet’s 
syndrome, PYG, generalized gonococcal infection, subacute 
bacterial endocarditis and systemic candidiasis [68].
The histological picture of the skin lesions is characterized 
by edema of the papillary dermis, mononuclear and eosino-
philic perivascular infiltration, intraepidermal pustules, mild 
or minute alterations of the walls of capillaries and venules 
without the typical features of leukocytoclastic vasculitis 
[7,44,48]. Deposition of immunoglobulins and complement is 
usually observed at the dermo-epidermal junction by immuno-
fluorescence. Deposition of circulating immune complexes in 
the skin and the joints that are formed due to immunological 
response against antigenic peptidoglycans of intestinal bacteria 
is thought to be involved in the pathogenesis of the syndrome, 
whereas the pathophysiology of the cutaneous manifestations 
is similar to that of PYG [48,68].
The management of the bowel-associated dermatosis-
arthritis syndrome includes the treatment of the underlying 
disorder and the administration of systemic antibiotics for 
inhibition of bacterial growth (tetracyclines, metronidazole, 
ciprofloxacin, trimethoprim-sulphamethoxazole) and of sys-
temic steroids, sulfone, colchicine or sulfasalazine for inhibition 
of neutrophils [48].
C U TA N E OU S 	 D I S OR D E R S 	 C OMMON lY	
A S S O C I A T E D 	w I T H 	 I B D
a.	Acquired	epidermolysis	bullosa is a rare, chronic, 
non-inflammatory, autoimmune bullous disorder of the skin 
and mucosae that predominantly occurs in patients with long 
standing CD [7,71]. Its clinical picture is characterized by 
increased skin fragility and formation of bullae, erosions and 
scars primarily in regions commonly exposed to mechanical 
trauma (extensor surface of the extremities, fingers and toes). 
The histological picture is characterized by subepidermal bulla 
with an inflammatory infiltrate of varying intensity in the der-
mis. Direct immunofluorescence reveals a linear deposition 
of IgG along the dermoepidermal junction, which on electron 
microscopy is found to be located under the lower part of 
lamina densa. Immunoblotting shows circulating autoantibodies 
against the major 290 kDa protein type VII collagen α-chain 
and the minor 145 kDa protein [72]. The pathogenesis of the 
disease is linked to autoantibodies of the IgG-isotype against 
collagen VII, which is a normal constituent of anchoring fibrils 
and the basal lamina of normal colon mucosa [71]. In patients 
with co-occurrence of IBD and acquired epidermolysis bul-
losa, autoantibodies formed in the course of the intestinal 
disease are bound to collagen VII of intestinal mucosa and 
cause epithelial damage and unmasking of antigenic epitopes 
of collagen VII. IgG autoantibodies produced against these 
epitopes bind to collagen VII of epidermal basal lamina and 
cause the bulla formation.
Intravenous immunoglobulin represents the treatment 
of choice particularly for patients with recurrent and rapidly 
progressive severe and extensive disease [72], whereas the 
therapeutic response to systemic steroids, dapsone, phenytoin, 
colchicine or immunosuppressive agents is rather poor. Plas-
mapheresis or extracorporal photochemotherapy could be 
considered only in those rare cases which reveal a partial 
resolution under systemic steroids.
b.	Bullous	pemphigoid	and	linear	IgA	bullous	dermatosis 
predominantly occur in patients with UC [73] and rarely in 
those with CD [74]. Bullous pemphigoid is an autoimmune 
blistering disorder of the skin and mucosae associated with 
autoantibodies directed against the normal components of 
hemidesmosomes (BP 180 and BP 230), and predominantly 
affects the elderly. It is characterized by an initial urticarial 
eruption, which progressively develops into large and tense, 
round or oval bullae scattered throughout the body. Histology 
reveals an eosinophil-rich subepidermal bulla with eosinophilic 
and lymphocytic perivascular infiltrate in the upper dermis, 
whereas direct immunofluorescence shows a linear deposition 
of IgG and C3 to the epidermal side of the basement membrane 
zone. Treatment consists of oral tetracycline and nicotinamide, 
dapsone or prednisolone (with or without an immunosuppres-
sant) and in mild cases of topical corticosteroids.
Linear IgA bullous dermatosis is a rare, acquired subepider-
mal blistering disease characterized by linear deposition of IgA 
along the basement membrane (on direct immunofluorescence) 
and by pruritic, symmetric, grouped annular crusted papules, 
vesicles or bullae particularly on the extensor surfaces of the 
extremities and on the buttocks. Histology reveals a subepi-
dermal bulla with a predominantly neutrophilic inflammatory 
infiltrate in the superficial dermis. Oral dapsone is the drug 
of choice for the treatment of this disorder. Alternatively, 
oral sulfapyridine, mycophenolate mofetil, colchicines and 
intravenous immunoglobulins can also be beneficial.
c.	Hidradenitis	suppurativa	(acne	inversa). It is a chronic 
relapsing inflammatory skin disorder of unknown etiopatho-
genesis, which is characterized by recurrent draining sinuses 
and abscesses predominantly occurring in intertriginous 
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areas and on the genital skin [75,76]. It mostly occurs in CD 
patients with colon involvement after the manifestation of the 
intestinal disease and is characterized by follicular obstruc-
tion and secondary bacterial infection [77]. Histology reveals 
inflammation and/or abscess of hair follicles with granuloma 
and sinus tract formation and fibrosis. In our Department, 
oral administration of isotretinoin represents the treatment 
of choice for hidradenitis suppurativa. Antibiotics (metroni-
dazole, minocyclin, clindamycin, erythromycin), steroids and 
anti-TNF agents have only moderate and temporary therapeutic 
results. Surgical procedures such as excision or drainage are 
rarely necessary [77,78]. A careful follow-up is required for 
early diagnosis and treatment of squamous cell carcinoma 
that may develop in the lesional skin [79].
d.	Phlebitis	and	periphlebitis occur in >30% of patients 
with UC but are rarely observed in those with CD. Their 
pathogenesis is thought to be associated with the predisposition 
for hypercoagulability due to thrombocytosis and increased 
factor VIII activity observed in patients with IBD. Several 
cases of cryoglobulinemia and gangrene have been reported 
in CD, whereas cryofibrinogenemia and arterial thromboses 
at the fingers, arms and the penis are rare. The histological 
features resemble those of disseminated intravascular coagula-
tion [9]. The management of these disorders includes standard 
conservative measures (leg elevation, warm compresses, 
anti-inflammatory and anticoagulation drugs) and surgical 
procedures.
e.	Erythema	multiforme	and	urticaria are observed in 
patients with IBD either as a hypersensitivity reaction to the 
intestinal disease or as a side effect of therapy [7]. Erythema 
multiforme is an acute disease of the skin and mucosae that 
ranges from a self-limiting cutaneous eruption to a progressive 
severe mucocutaneous disorder (Stevens-Johnson syndrome). 
The former is characterized by maculopapules or vesicles with 
a red periphery and a cyanotic centre (iris or target lesions) 
localized on the extremities and less often on the trunk and 
the face. In the severe form, oral mucosae, eyes, skin and 
anogenital region show extensive bullae with erosions and 
haemorrhagic crusts. The main histological findings include 
keratinocyte necrosis of variable severity, hydropic degenera-
tion of basal keratinocytes, intraepidermal vesiculation and 
lymphohistiocytic infiltrate. Urticaria is characterized by the 
occurrence of mostly transient and pruritic edematous papules, 
which on light microscopy predominantly reveal dermal edema 
and sparse perivascular lymphocytic and eosinophilic infiltrate. 
Systemic administration of steroids is the treatment of choice 
for all forms of erythema multiforme and for severe urticaria 
whereas in mild forms of the latter systemic antihistamines 
are beneficial.
f. Other disorders occasionally occurring in patients with 
IBD are lichen	planus	or	nitidus,	secondary	amyloidosis,	viti-
ligo	and	psoriasis [7,15,38]. Psoriasis, in particular, is observed 
in 8.9% of patients with CD and is thought to be genetically 
and immunologically linked to the latter since:
I. Certain loci identified on chromosomes 3, 4, 6 and 16 are 
associated with both psoriasis and CD.
II. TNF-α and IFN-γ produced by Th1 lymphocytes are 
involved ιn the pathogenesis of these two disorders and 
induce a delayed-type hypersensitivity reaction.
III. Psoriasis and CD reveal a favorable response to compounds 
that target T-lymphocytes or Th1 cytokines, such as TNF-
inhibitors or immunomodulatory drugs [80].
g. In some rare cases, squamous	cell	carcinoma	and	
Bowen’s	disease can develop on the apparently healthy skin of 
perianal region or around colostomies or ileostomies or in the 
perianal skin tags of patients with IBD. The immunosuppression 
associated with the intestinal disease or with its treatment is 
involved in the pathogenetic mechanisms of these neoplasms 
since it favors the carcinogenetic action of HPV [15]. Surgical 
excision is the treatment of choice for both neoplasms.
S E CON DA RY 	 C U TA N E OU S	
M A N I F E S T A T I ON S 	 O F 	 I B D
They are due either to the complications of IBD (particu-
larly malabsorption) or to the side effects of the treatment of 
the intestinal disease.
A. The cutaneous manifestations due to malabsorption 
include:
1.	 Acrodermatitis	enteropathica, which is caused by the 
reduced serum zinc levels and is manifested as dermatitis 
on the extremities, alopecia and diarrhea. Dermatitis is 
characterized by dry, scaly, eczematous or vesiculopustular 
lesions located around the stomata, on the face, scalp and 
the anogenital region. Treatment consists of oral adminis-
tration of zinc sulphate at a daily dose of 220 mg [7,44].
2.	 Pellagra	and	scurvy due to niacin and ascorbic acid defi-
ciency.
3.	 Purpura due to vitamin C and k deficiency.
4.	 Stomatitis,	glossitis	and	angular	cheilitis due to vitamin 
B deficiency.
5.	 Xeroderma	and	unspecific	eczematous	lesions due to 
essential fatty acid deficiency.
6.	 Hair	and	nail	abnormalities due to reduced amino acid 
and protein absorption [7].
In all these disorders substitution of the deficient factors 
leads to a complete resolution of the cutaneous lesions.
B. The cutaneous manifestations due to side-effects of 
treatment include:
1.	 Cutaneous	side-effects	of	drugs	used	in	the	treatment	of	
IBD	(Table	3).
2.	 Peristomal	dermatitis	and	ulceration:
 a. Peristomal toxic or allergic contact dermatitis is due 
to leakage of the intestinal content, excretions of fistules 
and to contact with adhesive tapes οr detergents [7]. The 
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TABlE	3. Cutaneous side-effects of drugs used in the treatment of inflammatory bowel disease (IBD)
Drugs Cutaneous	side-effects
5-amino-salicylic acid Lichen planus, vasculitis, urticaria, edema, (salazosulfapyridine, skin hypersensitivity reaction sulfasalazine, 
mesalazine, sulfapyridine)
Metronidazole Fixed and bullous drug eruption, acute generalized pustulosis, linear IgA bullous dermatosis, pruritus, urti-
caria
Ciprofloxacin Leukocytoclastic and necrotic vasculitis, toxic epidermal necrolysis, erythema, pruritus, urticaria, phototoxicity, 
angioedema, erythema multi-forme, fixed drug eruption, Stevens-Johnson syndrome
Azathioprine Stevens-Johnson syndrome, papular and maculopapular exanthema, urticaria, angioedema, erythema mutli-
forme, peeling syndrome, squamous cell and Merkel carcinoma, hair loss, pruritus, lymphoma
6-Mercaptopurine Skin hyperpigmentation, pruritus, hair loss, papular exanthema, bullous reaction, yellow discoloration of skin, 
nail hyperpigmentation, injection site reactions, ulcerations of oral mucosa
Methotrexate Vasculitis, pseudolymphoma, ulceration of oral mucosa and skin, papular eruption, bullous der-matosis, ony-
cholysis, toxic epidermal necrolysis, hair loss, pruritus, acne, phototoxicity, squamous cell carcinoma
Cyclosporin Acne, hypertrichosis, gingival hyperplasia, squamous cell carcinoma, lymphoma, anaphylaxis, verrucae vulgares, 
sebaceous gland hyperplasia, epidermal cysts, folliculitis, leukocytoclastic vasculitis, purpura
Systemic steroids Skin infections, dermatitis, xeroderma, purpura, striae, skin atrophy, skin cancer, acneiform eruption, teleangi-
ectases, skin depigmentation, hypertrichosis, kaposi’s sarcoma
Anti-TNF Leukocytoclastic vasculitis, lichenoid drug erup-tion, perniosis-like eruption, granuloma annulare, folliculitis, 
serum sickness, psoriasiform and bullous reaction, erythema multiforme-like reaction, squamous cell carcino-
ma, systemic lupus erythematosus, necrotising fasciitis, T- and B-cell lymphoma, kaposi’s sarcoma, skin infec-
tions, injection site reactions, cutaneous ulcerations, Stevens-Johnson syndrome, eczematid-like purpura
Mycophenolate mofetil Severe psoriasiform eruption, acne, dyshidrotic eczema, peripheral edema, skin cancer (squamous cell carci-
noma, lymphoma) fungal and viral cutaneous infections
Thalidomide Morbilliform exanthema, urticaria, vasculitis, brittle nails, dry mouth, erythema nodosum, erythroderma, pru-
ritus, pustular eruption, red palms, toxic epidermal necrolysis, purpura, facial and limb edema, exfoliative reac-
tions
Tacrolimus Pruritus
GMCSF Maculopapular eruption, injection site reactions
Tra nsdermal nicotine Pruritus, hyperalgesia, allergic and toxic contact dermatitis
management of this dermatitis includes the topical or 
intralesional administration of steroids and the use of 
protective tapes and nonirritating detergents [9].
 b. Peristomal ulceration is due to fistula formation, peristo-
mal PYG, infected hematoma or to pressure from a poorly 
fitting device [81]. Topical application of antibiotics and/or 
granulocyte-macrophage-stimulating factor and treatment 
of PYG and fistulae are helpful.
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